NCT07218913 2026-04-17
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
201 trialsNCT04286386 2026-04-16
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
M.D. Anderson Cancer Center
Active not recruiting
NCT03575611 2026-04-15
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05047965 2026-04-15
An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05055843 2026-04-15
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05960578 2026-04-14
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT06421142 2026-04-13
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
First Affiliated Hospital of Fujian Medical University
Phase NA Active not recruiting
NCT07526545 2026-04-13
UPRISE
University of Michigan Rogel Cancer Center
Phase NA Not yet recruiting
NCT05053152 2026-04-08
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting
NCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07097142 2026-04-08
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06931340 2026-04-07
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07000084 2026-04-07
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06389786 2026-04-06
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Mayo Clinic
Phase NA Recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05946213 2026-04-03
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT06500455 2026-04-03
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT02664883 2026-04-02
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
University of Southern California
Active not recruiting
NCT06325046 2026-03-31
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
Mayo Clinic
Phase NA Recruiting
NCT06526299 2026-03-24
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT02722525 2026-03-23
Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Active not recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT05245006 2026-03-17
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
University of California, San Francisco
Phase 1 Active not recruiting
NCT05888532 2026-03-17
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Phase 1/2 Recruiting
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT04190446 2026-03-16
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07025369 2026-03-13
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
Phase 2 Recruiting
NCT07332351 2026-03-13
TRIFECTA
University of Washington
Phase 2 Not yet recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT07466498 2026-03-12
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
University of Washington
Phase 2 Not yet recruiting
NCT07075705 2026-03-11
Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
Roswell Park Cancer Institute
Phase NA Not yet recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07164027 2026-03-10
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06330805 2026-03-09
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03085043 2026-03-05
Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06675357 2026-03-04
Using FAPI PET/MRI to Evaluate Prostate Cancer
University of Wisconsin, Madison
Phase 2 Recruiting
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT07128680 2026-02-27
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT04258462 2026-02-23
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT04006522 2026-02-20
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT03933670 2026-02-18
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
University of California, San Francisco
Phase 2 Recruiting
NCT06470282 2026-02-18
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
Phase 1/2 Recruiting
NCT05641935 2026-02-17
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
Thomas Jefferson University
Phase 2 Recruiting
NCT06236139 2026-02-17
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT06625034 2026-02-10
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
Phase 3 Recruiting